Impact of Lactiplantibacillus plantarum Inducia on metabolic and antioxidative response in cholesterol and BMI variable indices: randomised, double-blind, placebo-controlled trials

Abstract

Probiotics may have potential in reducing cardiovascular disease (CVD) risk in middle-aged persons with borderline metabolic indices. The ability of potential probiotic Lactiplantibacillus plantarum Inducia to reduce CVD risk factors in persons with variable cholesterol and body mass indices (BMI) was assessed. In two parallel-armed double-blind placebo-controlled interventions (n=136) and (n=104), participants daily received either test yoghurt (Inducia) or placebo yoghurt. BMI, blood pressure, plasma glucose, cholesterol, high-sensitivity C-reactive protein (hs-CRP), oxidative stress and immunological markers were measured. Total counts of lactobacilli and L. plantarum Inducia were evaluated using real-time PCR. Significant reduction of total cholesterol, low density lipoprotein cholesterol (LDL-c) and non-high-density cholesterol occurred in both trials. The change in cholesterol (P=0.023) in persons with normal BMI and borderline cholesterol levels after four weeks of yoghurt consumption was detected. A difference was also found between placebo and test yoghurt groups (P=0.042) in LDL-c with normal BMI. Blood glucose reduction (P=0.01) and antioxidative effect was detected in overweight volunteers of the test yoghurt group. The suppression of oxidised LDL was associated with lowered oxidative stress index and total peroxide concentration values and faecal recovery of Inducia. The Inducia strain expresses antioxidative effect on blood lipids and has anti-glycaemic impact that allow to apply it as dietary probiotic supplement for the management of CVD risks in humans.

A 12-Week, Single-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Design Clinical Trial for the Evaluation of the Efficacy and Safety of Lactiplantibacillus plantarum SKO-001 in Reducing Body Fat

“…In clinical studies, L. plantarum has been shown to alter cholesterol levels in individuals with normal weight or borderline cholesterol levels [ 20 ]. In a non-alcoholic fatty liver disease mouse model fed a high-fat, high-fructose diet for 10 weeks, supplementation with L. plantarum prevented body weight gain, improved glucose and lipid homeostasis, reduced white fat inflammation, and reduced the progression of non-alcoholic fatty liver disease.…”

The Use of Microbial Modifying Therapies to Prevent Psoriasis Exacerbation and Associated Cardiovascular Comorbidity

“… [ 98 ] Lactiplantibacillus plantarum 2 parallel-armed double-blind placebo-controlled interventions ( n = 136 and n = 104), daily test yoghurt (Inducia) or placebo yoghurt BMI, blood pressure, plasma glucose, cholesterol, high-sensitivity C-reactive protein (hs-CRP), oxidative stress, and immunological markers were measured Significant reduction of total cholesterol (LDL-c) and non-high-density cholesterol A difference was also found between placebo and test yoghurt groups ( P = 0.042) in LDL-c with normal BMI. Blood glucose reduction ( P = 0.01) antioxidative effect in overweight volunteers of the test yoghurt group [ 99 ] Preclinical rat Limosilactobacillus fermentum 139 , L. fermentum 263 , and L. fermentum 296 Mixed formulation Female rats fed a high-fat diet (HFD) twice a day for 4 weeks Cardiometabolic parameters, inflammatory markers, short-chain fatty acid (SCFA) fecal contents, and oxidative stress in colon, liver, heart, and kidney tissues Increased acetate and succinate fecal contents Reduced hyperlipidemia and hyperglycemia in rats fed with HFD Decreased low-grade inflammation Improved antioxidant capacity along the gut, liver, heart, and kidney tissues [ 101 ] Clinical trials and case studies Clinical trial B. infantis 3562 3 separate randomized, double-blind, placebo-controlled interventions Patients with ulcerative colitis (UC) ( n = 22), chronic fatigue syndrome (CFS) ( n = 48), and psoriasis ( n = 26) Oral administration, for 6‒8 weeks Inflammatory biomarker and plasma cytokine levels Reduced plasma CRP levels in all 3 inflammatory disorders compared with placebo Reduced plasma TNF-α in CFS and psoriasis [ 91 ] Clinical trial Bifidobacterium longum CECT 7347, B. lactis CECT 8145, and Lactobacillus rhamnosus CECT 8361 Total 1 × 10 9 CFU per capsule 12-week randomized, double-blind, placebo-controlled trial Oral administration 12-week follow-up, reduction in PASI of at least 75% ( P < 0.05) and PGA 6 months...…”